1-(4'-propiophenone)pyrazole | 152008-63-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4'-propiophenone)pyrazole
• 英文别名: 1-(4-(1H-pyrazol-1-yl)phenyl)propan-1-one；1-Propanone, 1-[4-(1H-pyrazol-1-yl)phenyl]-；1-(4-pyrazol-1-ylphenyl)propan-1-one
• CAS: 152008-63-4
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: UNOPAXZCGUOULN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4'-propiophenone)pyrazole 在 吡啶 、 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 (E)-1-(4-(1H-pyrazol-1-yl)phenyl)propan-1-one O-perfluorobenzoyl oxime
  参考文献：
  名称：

  通过配体促进未应变酮的 C-C 键裂解构建 C(sp2)-Si 键

  摘要：

  在此，我们报道了通过 C-C 键断裂和 C-Si 键形成有效的钯催化的芳基和烯基酮的硅烷化。该协议具有高效率和广泛的基板范围。在生物重要分子的后期多样化中的进一步应用证明了这种方法的综合效用。

  DOI：

  10.1021/acs.orglett.2c02841
• 作为产物：
  描述：

  吡唑 、 4'-溴苯丙酮 在 copper(l) iodide 、 potassium carbonate 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以98%的产率得到1-(4'-propiophenone)pyrazole
  参考文献：
  名称：

  铜-二胺催化的吡咯，吡唑，吲唑，咪唑和三唑的N-芳基化

  摘要：

  本文详细介绍了铜催化的π-过量氮杂环的N-芳基化反应。芳基碘化物或芳基溴化物与常见的氮杂环（吡咯，吡唑，吲唑，咪唑和三唑）的偶联成功地用衍生自二胺配体和CuI的催化剂进行了高收率的偶联。发现一般条件可耐受芳基卤化物或杂环上的官能团，例如醛，酮，醇，伯胺和腈。使用本文报道的条件，受阻的芳基卤化物或杂环也被发现是合适的底物。

  DOI：

  10.1021/jo049658b

文献信息

• Copper−Diamine-Catalyzed <i>N</i>-Arylation of Pyrroles, Pyrazoles, Indazoles, Imidazoles, and Triazoles
  作者：Jon C. Antilla、Jeremy M. Baskin、Timothy E. Barder、Stephen L. Buchwald

  DOI：10.1021/jo049658b

  日期：2004.8.1

  This paper details the copper-catalyzed N-arylation of π-excessive nitrogen heterocycles. The coupling of either aryl iodides or aryl bromides with common nitrogen heterocycles (pyrroles, pyrazoles, indazoles, imidazoles, and triazoles) was successfully performed in good yield with catalysts derived from diamine ligands and CuI. General conditions were found that tolerate functional groups such as

  本文详细介绍了铜催化的π-过量氮杂环的N-芳基化反应。芳基碘化物或芳基溴化物与常见的氮杂环（吡咯，吡唑，吲唑，咪唑和三唑）的偶联成功地用衍生自二胺配体和CuI的催化剂进行了高收率的偶联。发现一般条件可耐受芳基卤化物或杂环上的官能团，例如醛，酮，醇，伯胺和腈。使用本文报道的条件，受阻的芳基卤化物或杂环也被发现是合适的底物。
• Selective, Transition Metal‐free 1,2‐Diboration of Alkyl Halides, Tosylates, and Alcohols
  作者：Mingming Huang、Jiefeng Hu、Shasha Shi、Alexandra Friedrich、Johannes Krebs、Stephen A. Westcott、Udo Radius、Todd B. Marder

  DOI：10.1002/chem.202200480

  日期：2022.4.27

  simple and efficient strategy to access alkyl 1,2-bis(boronate esters) via regio- and diastereoselective diboration of readily available secondary and tertiary alkyl halides (Br, Cl, I), tosylates, and alcohols was developed. The use of KI and DMA is critical to the methodology, which circumvents the regio- and diastereoselectivity problems. The transformation showed a broad substrate scope (75 examples)

  开发了一种无过渡金属、简单且有效的策略，通过对容易获得的仲和叔烷基卤化物（Br、Cl、I）、甲苯磺酸酯和醇进行区域和非对映选择性二硼化来获得烷基 1,2-双（硼酸酯） 。 KI 和 DMA 的使用对该方法至关重要，它可以避免区域选择性和非对映选择性问题。该转化显示了广泛的底物范围（75 个实例）以及天然产物后期修饰的实用性。
• Spiroheptane salicylamides and related compounds as inhibitors of rock
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10611776B2

  公开（公告）日：2020-04-07

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)化合物：或其立体异构体、同系物或药学上可接受的盐，其中所有变量均如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
• SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190016735A1

  公开（公告）日：2019-01-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
• Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of <i>Mycobacterium tuberculosis</i>
  作者：W. David Hong、Peter D. Gibbons、Suet C. Leung、Richard Amewu、Paul A. Stocks、Andrew Stachulski、Pedro Horta、Maria L. S. Cristiano、Alison E. Shone、Darren Moss、Alison Ardrey、Raman Sharma、Ashley J. Warman、Paul T. P. Bedingfield、Nicholas E. Fisher、Ghaith Aljayyoussi、Sally Mead、Maxine Caws、Neil G. Berry、Stephen A. Ward、Giancarlo A. Biagini、Paul M. O’Neill、Gemma L. Nixon

  DOI：10.1021/acs.jmedchem.6b01718

  日期：2017.5.11

  A high-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). The 11000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, trifluoperazine and thioridazine. Combined HTS (11000 compounds) and in-house screening of a limited number of quinolones (50 compounds) identified similar to 100 hits and four distinct chemotypes, the most promising of which contained the quinolone core. Subsequent Mtb screening of the complete in-house quinolone library (350 compounds) identified a further similar to 90 hits across three quinolone subtemplates. Quinolones containing the amine-based side chain were selected as the pharmacophore for further modification, resulting in metabolically stable quinolones effective against multi drug resistant (MDR) Mtb. The lead compound, 42a (MTC420), displays acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable pharmacokinetic and toxicological profiles.